Successful treatment of acyclovir-resistant herpes simplex virus with intralesional cidofovir

Archives of Dermatology

Volumn 146, Issue 2, 2010, Pages 124-126

  Castelo Soccio, Leslie ^a   Bernardin, Ronald ^a   Stern, John ^a   Goldstein, Stephen A ^a   Kovarik, Carrie ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; CIDOFOVIR; CORTICOSTEROID; VANCOMYCIN;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DEBRIDEMENT; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; GENITAL HERPES; GRANULATION TISSUE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MALE; NEPHROTOXICITY; PATHOLOGY; PRIORITY JOURNAL; RHINECTOMY; SKIN BIOPSY; SKIN ULCER; SURGICAL TECHNIQUE; T CELL LYMPHOMA; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS LOAD; VIRUS RESISTANCE;

ACYCLOVIR; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOSINE; DRUG RESISTANCE, VIRAL; FACIAL DERMATOSES; HERPES SIMPLEX; HUMANS; INJECTIONS, INTRALESIONAL; MALE; PHOSPHONIC ACIDS;

EID: 76749114370     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.363     Document Type: Article

References (12)

1. Soma MA, Albert DM. Cidofovir: to use or not to use? Curr Opin Otolaryngol Head Neck Surg. 2008;16(1):86-90.
2. Tanna N, Sidell D, Joshi A, Bielamowicz SA. Adult intralesional cidofovir therapy for laryngeal papilloma: a 10-year perspective. Arch Otolaryngol Head Neck Surg. 2008;134(5):497-500.
3. Broekema FI, Dikkers FG. Side effects of cidofovir in the treatment of recurrent respiratory papillomatosis. Eur Arch Otorhinolaryngol. 2008;265(8):871-879.
4. Dikkers FG. Intralesional cidofovir does not increase the risk of laryngeal dysplasia or laryngeal carcinoma. Int J Pediatr Otorhinolaryngol. 2008;72(10):1581-1582.
5. Briand S, Milpied B, Navas D, Thomare P, Stalder JF. 1% topical cidofovir used as a last alternative to treat viral infections. J Eur Acad Dermatol Venereol. 2008; 22(2):249-250.
6. Cha S, Johnston L, Natkunam Y, Brown J. Treatment of verruca vulgaris with topical cidofovir in an immunocompromised patient: a case report and review of the literature. Transpl Infect Dis. 2005;7(3-4):158-161.
7. Toro JR, Sanchez S, Turiansky G, Blauvelt A. Topical cidofovir for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox. Dermatol Clin. 2003;21(2):301-309.
8. Kottke MD, Parker SR. Intravenous cidofovir induced resolution of disfiguring cutaneous human papilloma virus infection. J Am Acad Dermatol. 2006;55 (3):533-536.
9. Chilukuri S, Rosen T. Management of acyclovir resistant herpes simplex virus. Dermatol Clin. 2003;21(2):311-320.
10. Cundy KC, Lynch G, Lee WA. Bioavailability and metabolism of cidofovir following topical administration to rabbits. Antiviral Res. 1997;35(2):113-122.
11. Cundy KC, Li ZH, Hitchcock MJ, Lee WA. Pharmacokinetics of cidofovir in monkeys: evidence for prolonged elimination phase represents phosophorylated drug. Drug Metab Dispos. 1996;24(7):738-744.
12. Cundy KC, Bidgood AM, Lynch G, Shaw JP, Griffin L, Lee WA. Pharmacokinetics, bioavailability, metabolism and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Drug Metab Dispos. 1996;24(7):745-752.